Audit-ready report

Printable summary of the analysis

Ask iZO
DB
Synthetic, de-identified, aggregated data. Illustrative demo.
Back to Improve
iZO Patient Journey Analytics · Audit-ready report

Why has Brand X new-patient growth stalled?

Synthetic, de-identified, aggregated data. Illustrative demo. Generated October 14, 2026.

1. Cohort

40,000 new RA patients over 24 months, identified from RA diagnosis codes and lab markers. Median age 54; 67.6% with a comorbidity; 82.1% biologic-naive.

2. Therapy flow

Switches to advanced therapy happen late, at line 2 and line 3. Brand X wins 19.7% of those switches; competitors win 80.3%.

3. Drop-off

15,936 new Brand X prescriptions; 27.5% abandoned before first fill. Abandonment in Region North-East and Region Mid-South is 39.7% versus 23.0% elsewhere, a gap of 16.7 points. Abandonment tracks closely with prior authorization rejections. Top reason: missing lab result.

4. Actions

  • Access (Director, Market Access): Review prior auth criteria with the top plans in Region North-East and Region Mid-South. Clarify which lab results are required up front. Status: not yet assigned.
  • Field (Regional Sales Directors): Flag 149 affected practices for a visit on prior auth requirements and lab result documentation. Status: not yet assigned.
  • Patient Services (Head of Patient Services): Add prior auth support for new Brand X prescriptions, including a missing lab result check before submission. Status: not yet assigned.

5. Result of the access push

Refreshed quarter not yet loaded. Refresh data on the Improve screen to include the latest results.
Data source: de-identified, aggregated claims. All analysis uses de-identified, aggregated patient data. No individual patient is identifiable. Field insight is shown at practice level only.